The Case For Patient Diversity In Clinical Trials

Two of America’s greatest assets are its diverse demographics and its relentless pursuit of new medicines and treatments to improve patient lives worldwide. Unfortunately, it’s a widely known (but little discussed) challenge that the two do not go hand in hand. Minority participation in clinical trials is staggeringly deficient.

For example, America contains over 39 million African-Americans and 52 million Hispanic Americans. While these groups represent 28% of the nation, they only account for 6% of clinical trial patients.

It’s critical that the industry solves this challenge soon, as it is only going to intensify over time. By 2050, minorities will account for more than half of the American population with Hispanic populations representing more than 29% of the nation.